Patent US1829603A successfully refreshed from Google Patents.
US4309989A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Topical application of medication by ultrasound with coupling agent
Assignee: FAHIM MOSTAFA S
•
Filing: 1978-08-14
•
Granted: 1982-01-12
•
Expires: 1998-08-14
Abstract
Abstract A method of topically applying an effective medication in an emulsion coupling agent by ultrasound. More particularly, a method of treating a skin condition by applying a medication in an emulsion coupling agent and massaging it into the affected area with ultrasonic vibrations thereby causing the medication to penetrate into the skin. Specifically, a method and composition for the treatment of Herpes Simplex Type 1 and Type 2 lesions. Also specifically, a method and composition for the treatment of demidox mites.
Inventors
- 👤 Mostafa S. Fahim
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 12:17
CPC Classifications
A; A61; A61M; A61M37/00; A61M37/0092; A61K; A61K33/00; A61K33/24; A61K33/30
Claims Analysis
Total Claims: 7
Claim 1
Independent Claim
130 words
In the treatment of Herpes Simplex lesions, a method for the selective localized intracellular administration of a medication including urea and a zinc compound in a coupling agent, the urea and zinc compound being present in an effective amount, which comprises applying said medication to the affected area and massaging said medication therein with an ultrasonic applicator coupled to an ultrasonic generator, said applicator continuously vibrating at a frequency of at least 1,000 KHZ and having an effective power level from about 1 watt per sq. cm to about 3 watts per sq. cm for a time sufficient to obtain intracellular penetration of said medication without causing undo cell wall deterioration whereby the zinc amplifies the mechanical effects of the ultrasonic vibrations and the urea acts as an antiviral agent.
Claim 2
Dependent Claim
130 words
In the treatment of Herpes Simplex lesions, a method for the selective localized intracellular administration of a medication including urea and a zinc compound in a coupling agent, the urea and zinc compound being present in an effective amount, which comprises applying said medication to the affected area and massaging said medication therein with an ultrasonic applicator coupled to an ultrasonic generator, said applicator continuously vibrating at a frequency of at least 1,000 KHZ and having an effective power level from about 1 watt per sq. cm to about 3 watts per sq. cm for a time sufficient to obtain intracellular penetration of said medication without causing undo cell wall deterioration whereby the zinc amplifies the mechanical effects of the ultrasonic vibrations and the urea acts as an antiviral agent.
Claim 3
Dependent Claim
19 words
The method for treatment of Herpes Simplex lesions according to claim 1 wherein the medication further includes an astringent.
Claim 4
Dependent Claim
29 words
The method for treatment of Herpes Simplex lesions according to claim 2 wherein the urea is present in an amount from about 5 to about 40 percent by weight.
Claim 5
Dependent Claim
84 words
The method for treatment of Herpes Simplex lesions according to claim 3 wherein the lesions are Type 1 lesions and wherein the astringent is tannic acid, said urea being present in an amount from about 10 percent to about 30 percent by weight, said zinc compound is zinc oxide and is present in an amount from about 0.5 percent to about 3 percent by weight and said tannic acid is present in an amount from about 0.5 percent to about 2 percent by weight.
Claim 6
Dependent Claim
47 words
The method for treatment of Herpes Simplex Type 1 lesions according to claim 4 wherein the medication further includes menthol in an amount from about 0.25 percent to about 1 percent and ethyl alcohol in an amount from about 0.30 percent to about 1 percent by weight.
Claim 7
Dependent Claim
84 words
The method for treatment of Herpes Simplex lesions according to claim 3 wherein the lesions are Type 2 lesions and wherein the astringent is tannic acid, said urea being present in an amount from about 10 percent to about 40 percent by weight, said zinc compound is zinc oxide and is present in an amount from about 1 percent to about 5 percent by weight and said tannic acid is present in an amount from about 1 percent to about 5 percent by weight.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1985-01-11 | 1985-07-13 | 1986-01-12 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1989-01-11 | 1989-07-13 | 1990-01-12 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1993-01-11 | 1993-07-13 | 1994-01-12 | $7700.00 | Window Closed / Lapsed |